GW - Schizophrenia Treatment

GW’s cannabinoids have shown notable anti-psychotic effects in pre-clinical models of schizophrenia and in September 2015, we announced positive top line results from an exploratory Phase 2a placebo-controlled clinical trial of a CBD formulation in 88 patients with schizophrenia who had previously failed to respond adequately to first line anti-psychotic medications. In this study, our CBD formulation demonstrated significantly reduced positive symptoms and significantly improved the clinical global impression of improvement, compared to placebo.

GW is now moving forward with a follow-on phase 2b placebo-controlled study aimed at further estimating the magnitude of the treatment effect of an investigational CBD-containing product on positive, negative and general symptoms of schizophrenia. We expect to initiate enrollment in 2020.